Key Events This Week
Mar 09: Stock surges 7.31% amid heavy buying, Sensex falls 1.91%
Mar 11: Hits upper circuit with nearly 10% gain, strong volume spike
Mar 12: New 52-week high at Rs.912, Mojo rating downgraded to Hold
Mar 13: Reaches all-time high Rs.946.1, upgraded back to Buy, but hits lower circuit amid profit booking
March 9: Strong Start Amid Market Weakness
Venus Remedies Ltd began the week with a robust 7.31% gain to close at Rs.755.25, driven by strong buying interest. This performance was in stark contrast to the Sensex, which declined 1.91% to 34,557.39. The stock’s volume of 4,443 shares indicated active participation, setting the tone for the week’s momentum despite a broadly negative market environment.
March 10: Continued Gains with Market Recovery
The stock extended its rally, rising 3.89% to Rs.784.65, outpacing the Sensex’s 1.30% gain. Although volume dipped to 2,840 shares, the steady price increase reflected sustained investor confidence. The broader market’s modest recovery provided a supportive backdrop for Venus Remedies’ upward trajectory.
March 11: Upper Circuit Hit on Surge of Buying Pressure
Venus Remedies Ltd surged to an upper circuit limit with a near 10% gain, closing at Rs.863.10. This marked a fresh 52-week and all-time high, underscoring intense buying pressure amid a declining Sensex (-1.36%). The stock’s trading range was wide, with a low of Rs.779.05 and a high of Rs.861.7, reflecting heightened volatility. Volume spiked to 10,596 shares, with delivery volumes increasing by 228.56%, signalling strong investor participation. Despite the regulatory freeze capping further gains, the unfilled demand suggested continued momentum potential.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
March 12: New 52-Week High Amid Mixed Technical Signals and Rating Downgrade
The stock reached a new 52-week high of Rs.912, gaining 7.46% intraday before closing at Rs.927.50, despite the Sensex falling 0.66%. This extended the stock’s winning streak to seven consecutive sessions, delivering a 39.01% return over this period. However, MarketsMOJO downgraded the rating from Buy to Hold on 11 Mar 2026, citing valuation concerns despite strong financials. The company’s price-to-book ratio of 1.9 and a PEG ratio of 0.1 suggested premium pricing, while some weekly technical indicators showed mild bearishness. Institutional interest remained strong, with holdings rising to 3.28%.
March 13: All-Time High, Upgrade, and Sharp Correction
Venus Remedies Ltd hit an all-time high of Rs.946.1 intraday, reflecting sustained bullish momentum. The stock’s technical grade was upgraded back to Buy by MarketsMOJO on 12 Mar 2026, supported by improved moving averages, bullish Bollinger Bands, and a Mojo Score of 74.0. Despite this, the stock closed lower at Rs.894.05, down 3.61%, after hitting the lower circuit limit of Rs.881.15 amid heavy selling pressure and profit-booking. The intraday volatility was high at 5.36%, with a turnover of ₹3.10 crore. This sharp correction followed a prolonged rally and was sharper than the sector’s 1.16% decline and the Sensex’s 1.31% fall, signalling a temporary exhaustion of buying interest.
Want to dive deeper on Venus Remedies Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Daily Price Comparison: Venus Remedies Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-09 | Rs.755.25 | +7.31% | 34,557.39 | -1.91% |
| 2026-03-10 | Rs.784.65 | +3.89% | 35,005.20 | +1.30% |
| 2026-03-11 | Rs.863.10 | +10.00% | 34,529.78 | -1.36% |
| 2026-03-12 | Rs.927.50 | +7.46% | 34,300.49 | -0.66% |
| 2026-03-13 | Rs.894.05 | -3.61% | 33,516.43 | -2.29% |
Key Takeaways
Positive Signals: Venus Remedies Ltd demonstrated exceptional price appreciation of 27.03% over the week, vastly outperforming the Sensex’s 4.87% decline. The stock hit multiple new 52-week highs and an all-time peak of Rs.946.1, supported by strong quarterly earnings growth of 96.37% in operating profit and 116.9% in PAT. Technical indicators across daily and monthly timeframes turned bullish, with moving averages and Bollinger Bands confirming upward momentum. Institutional investors increased their stake to 3.28%, signalling growing confidence.
Cautionary Signals: Despite the strong rally, the stock experienced a sharp correction on 13 Mar 2026, hitting the lower circuit amid heavy selling pressure and profit-booking. The MarketsMOJO rating briefly downgraded to Hold on 11 Mar 2026 due to valuation concerns, with a price-to-book ratio of 1.9 and a PEG ratio of 0.1 indicating premium pricing. Some weekly technical indicators such as MACD and KST showed mild bearishness, suggesting potential short-term volatility. The company’s net sales growth remains modest at 6.29% CAGR over five years, which may temper long-term expectations.
Conclusion
Venus Remedies Ltd’s week was characterised by a powerful rally that defied broader market weakness, driven by strong financial results, technical momentum, and increased institutional interest. The stock’s ability to hit new highs amid a declining Sensex highlights its relative strength within the Pharmaceuticals & Biotechnology sector. However, the sharp correction and mixed technical signals on the final trading day underscore the importance of cautious monitoring. Investors should weigh the company’s robust earnings growth and improved technical outlook against valuation premiums and potential short-term volatility. Overall, Venus Remedies remains a compelling micro-cap stock with significant upside demonstrated this week, balanced by the need for prudent risk management.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
